Compare TITN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | ARVN |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 516.2M |
| IPO Year | 2007 | 2018 |
| Metric | TITN | ARVN |
|---|---|---|
| Price | $19.98 | $8.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $19.00 | $15.05 |
| AVG Volume (30 Days) | 147.5K | ★ 647.9K |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,427,107,000.00 | $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.21 | $6.06 |
| 52 Week High | $25.00 | $14.22 |
| Indicator | TITN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 42.94 |
| Support Level | $18.72 | $7.90 |
| Resistance Level | $20.21 | $8.90 |
| Average True Range (ATR) | 0.73 | 0.31 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 91.68 | 6.00 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.